FDA details safety plan, including monitoring (The Star-Ledger)
WASHINGTON — The Food and Drug Administration yesterday outlined a series of new safety initiatives in response to harsh criticism that it has failed to adequately protect the public from problem drugs like the painkiller Vioxx.